Companies Dominating the Non-Hodgkin Lymphoma Therapeutics Market
- AbbVie, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GSK plc.
- Novartis AG
- Bayer AG
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- SIRPant Immunotherapeutics Inc.
Browse Key Market Insights with Data Illustration:
In the News
- SIRPant-M's investigational new drug (IND) application got FDA approval in May 2023 after reviewing preclinical data that indicated the medication was effective against a range of solid tumours as well as hematologic tumours.
- AbbVie announced that EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) that have undergone two or more lines of systemic therapy and are relapsed or refractory (R/R).
